Newly appreciated therapeutic effect of GLP-1 receptor agonists: reduction in postprandial lipemia.
Bandsma
Robert H J
RH
Department of Medicine, University of Toronto, Toronto, Ontario, Canada M5G 2C4.
Lewis
Gary F
GF
D053283:Apolipoprotein B-48 / Q000097:blood; D053305:Apolipoprotein C-III / Q000097:blood; D015415:Biomarkers / Q000097:blood; D001786:Blood Glucose / Q000187:drug effects / Q000378:metabolism; D002784:Cholesterol / Q000097:blood; D003924:Diabetes Mellitus, Type 2 / Q000097:blood / Q000188:drug therapy*; D004041:Dietary Fats / Q000008:administration & dosage / Q000378:metabolism; D000077270:Exenatide; D005230:Fatty Acids, Nonesterified / Q000097:blood; D000067757:Glucagon-Like Peptide-1 Receptor; D006801:Humans; D006949:Hyperlipidemias / Q000097:blood / Q000517:prevention & control*; D007004:Hypoglycemic Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D007279:Injections, Subcutaneous; D007328:Insulin / Q000097:blood; D008074:Lipoproteins / Q000097:blood; D010455:Peptides / Q000008:administration & dosage / Q000627:therapeutic use*; D019518:Postprandial Period; D018027:Receptors, Glucagon / Q000819:agonists*; D013997:Time Factors; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood; D014688:Venoms / Q000008:administration & dosage / Q000627:therapeutic use*
D053283:Apolipoprotein B-48; D053305:Apolipoprotein C-III; D015415:Biomarkers; D001786:Blood Glucose; D004041:Dietary Fats; D005230:Fatty Acids, Nonesterified; C000593833:GLP1R protein, human; D000067757:Glucagon-Like Peptide-1 Receptor; D007004:Hypoglycemic Agents; D007328:Insulin; D008074:Lipoproteins; D010455:Peptides; D018027:Receptors, Glucagon; D014280:Triglycerides; D014688:Venoms; C112017:remnant-like particle cholesterol; D002784:Cholesterol; D000077270:Exenatide